<DOC>
	<DOCNO>NCT00828308</DOCNO>
	<brief_summary>Ixabepilone , 16 mg/m2 20mg/m2 , weekly x 3 , 4 week cycle , x 4 cycle . Prostatectomy 2-8 week completion ( standard care part study )</brief_summary>
	<brief_title>Neoadjuvant Weekly Ixabepilone High Risk , Clinically Localized Prostate Cancer</brief_title>
	<detailed_description>Ixabepilone , 16 mg/m2 20mg/m2 , weekly x 3 , 4 week cycle , x 4 cycle . Prostatectomy 2-8 week completion chemotherapy ( standard care ) . This protocol evaluate weekly ixabepilone prior robotic prostatectomy patient high risk localize prostate cancer . PSA response rate , tumor margin status pathologic response assess .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Histologic documentation prostatic adenocarcinoma . Patients small cell , neuroendocrine transitional cell carcinoma eligible . All eligible patient must know Gleason sum base biopsy TURP time registration . Clinically Localized Disease : Patients must clinical stage T1T3a radiographic evidence metastatic disease demonstrate : Either CT MRI abdomen pelvis , demonstrate node &gt; 1 cm : endorectal MRI ( If one lymph node ( ) measure &gt; 1 cm , negative biopsy require . ) Negative bone scan ( plain film /or MRI and/or CT scan confirmation , necessary ) . ( Positive PET Prostascint scan consider proof metastatic disease . ) Patients must high risk disease define either : Gleason Score 810 PSA &gt; 15 ng/ml Stage T3a Stage T2c Gleason score 7 Stage T2b , Gleason score 7 , great 50 % core positive single lobe . No prior treatment prostate cancer include prior surgery ( exclude TURP ) , pelvic lymph node dissection , radiation therapy , chemotherapy hormone therapy . Patient must appropriate candidate radical prostatectomy estimate life expectancy &gt; 10 year determine urologist . ECOG PS 01 Age &gt; 18 year age . Required initial laboratory value : ANC &gt; 1500/ul Platelet count &gt; 100,000/mm3 Creatinine &lt; 2.0 mg/dl Serum PSA &lt; 100 ng/ml Bilirubin &lt; upper institutional limit normal ( ULN ) AST/ALT &lt; 2.5 X ULN Active uncontrolled infection . Patients must coexistent medical condition would preclude protocol therapy . Previous severe hypersensitivity reaction drug formulate CremophoreL ( polyoxyethylated castor oil ) . Grade 1 great neuropathy ( motor sensory ) study entry</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>localize</keyword>
	<keyword>high risk</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>neoadjuvant treatment</keyword>
</DOC>